5ZWJ

Crystal structure of EGFR 675-1022 T790M/C797S/V948R in complex with EAI045

  • Classification: TRANSFERASE
  • Organism(s): Homo sapiens
  • Expression System: Spodoptera frugiperda
  • Mutation(s): 

  • Deposited: 2018-05-15 Released: 2018-07-25 
  • Deposition Author(s): Zhao, P., Yun, C.H.
  • Funding Organization(s): National Natural Science Foundation of China; Ministry of Education (China); Ministry of Science and Technology (China) 

Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.9 Å
  • R-Value Free: 0.272 
  • R-Value Work: 0.255 

wwPDB Validation 3D Report Full Report


This is version 1.0 of the entry. See complete history

Literature

Crystal structure of EGFR T790M/C797S/V948R in complex with EAI045.

Zhao, P.Yao, M.Y.Zhu, S.J.Chen, J.Y.Yun, C.H.

(2018) Biochem. Biophys. Res. Commun. 502: 332-337

  • DOI: 10.1016/j.bbrc.2018.05.154

  • PubMed Abstract: 
  • Lung cancer is the leading cause of cancer deaths. Epidermal growth factor receptor (EGFR) kinase domain mutations are a common cause of non-small cell lung cancers (NSCLCs), a major subtype of lung cancers. Patients harboring most of these mutations ...

    Lung cancer is the leading cause of cancer deaths. Epidermal growth factor receptor (EGFR) kinase domain mutations are a common cause of non-small cell lung cancers (NSCLCs), a major subtype of lung cancers. Patients harboring most of these mutations respond well to the anti-EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib initially, but soon develop resistance to them in about half of the cases due to the emergence of the gatekeeper mutation T790M. The third-generation TKIs such as AZD9291, HM61713, CO-1686 and WZ4002 can overcome T790M through covalent binding to the EGFR kinase through Cys 797, but ultimately lose their efficacy upon emergence of the C797S mutation that abolishes the covalent bonding. Therefore to develop new TKIs to overcome EGFR drug-resistant mutants harboring T790M/C797S is urgently demanded. EAI001 and EAI045 are a new type of EGFR TKIs that bind to EGFR reversibly and not relying on Cys 797. EAI045 in combination with cetuximab is effective in mouse models of lung cancer driven by EGFR L858R/T790M and L858R/T790M/C797S. Here we report the crystal structure of EGFR T790M/C797S/V948R in complex with EAI045, and compare it to EGFR T790M/V948R in complex with EAI001. The complex structure reveals why EAI045 binds tighter to EGFR than does EAI001, and why EAI001 and EAI045 prefer binding to EGFR T790M. The knowledge may facilitate future drug development studies targeting this very important cancer target.


    Organizational Affiliation

    Department of Biophysics, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China; Institute of Systems Biomedicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China; Beijing Key Laboratory of Tumor Systems Biology, Peking University Health Science Center, Beijing, 100191, China. Electronic address: yunch@hsc.pku.edu.cn.,Fengnan District Hospital, Tangshan, 063300, China.,Department of Biophysics, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China; Institute of Systems Biomedicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China; Beijing Key Laboratory of Tumor Systems Biology, Peking University Health Science Center, Beijing, 100191, China.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Epidermal growth factor receptor
A
355Homo sapiensMutation(s): 3 
Gene Names: EGFR (ERBB, ERBB1, HER1)
EC: 2.7.10.1
Find proteins for P00533 (Homo sapiens)
Go to Gene View: EGFR
Go to UniProtKB:  P00533
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
9LL
Query on 9LL

Download SDF File 
Download CCD File 
A
(2R)-2-(5-fluoro-2-hydroxyphenyl)-2-(1-oxo-1,3-dihydro-2H-isoindol-2-yl)-N-(1,3-thiazol-2-yl)acetamide
C19 H14 F N3 O3 S
YTUFHOKUFOQRDF-MRXNPFEDSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.9 Å
  • R-Value Free: 0.272 
  • R-Value Work: 0.255 
  • Space Group: P 61 2 2
Unit Cell:
Length (Å)Angle (°)
a = 79.586α = 90.00
b = 79.586β = 90.00
c = 215.075γ = 120.00
Software Package:
Software NamePurpose
PHENIXrefinement
HKL-2000data reduction
HKL-2000data scaling
PHASERphasing

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History & Funding Information

Deposition Data

  • Deposited Date: 2018-05-15 
  • Released Date: 2018-07-25 
  • Deposition Author(s): Zhao, P., Yun, C.H.

Funding OrganizationLocationGrant Number
National Natural Science Foundation of ChinaChina31270769
Ministry of Education (China)ChinaNCET-12-0013
Ministry of Science and Technology (China)China2012CB917202

Revision History 

  • Version 1.0: 2018-07-25
    Type: Initial release